Publications

• Tandem mass spectrometry and newborn screening: Pilot data and review
  Filiano, J. J., Bellimer, S. G., & Kunz, P. L. (2002). Tandem mass spectrometry and newborn screening: Pilot data and review. PEDIATRIC NEUROLOGY, 26(3), 201–204.
• Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus
  Vij, R., Triadafilopoulos, G., Owens, D. K., Kunz, P., & Sanders, G. D. (2004). Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus. GASTROINTESTINAL ENDOSCOPY, 60(5), 739–56.
• Escherichia coli O157 : H7 infection in nursing homes: Review of literature and report of recent outbreak
  Reiss, G., Kunz, P., Koin, D., & Keeffe, E. B. (2006). Escherichia coli O157 : H7 infection in nursing homes: Review of literature and report of recent outbreak. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 54(4), 680–84.
• Pathological response after chemoradiation for T3 rectal cancer. Chennupati, S. K., Kamaya, A., Fisher, G. A., Ford, J. M., Kunz, P., Itakura, H., … Chang, D. T. (2010). Pathological response after chemoradiation for T3 rectal cancer. Colorectal Disease , 12(7 Online), e24–30.
  
• Multimodality treatment with intensity modulated radiation therapy for esophageal cancer La, T. H., Minn, A. Y., Su, Z., Fisher, G. A., Ford, J. M., Kunz, P., … Chang, D. T. (2010). Multimodality treatment with intensity modulated radiation therapy for esophageal cancer. DISEASES OF THE ESOPHAGUS, 23(4), 300–308.
  
• Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis Chang, S. T., Zahn, J. M., Horecka, J., Kunz, P. L., Ford, J. M., Fisher, G. A., … Koong, A. C. (2009). Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. JOURNAL OF TRANSLATIONAL MEDICINE, 7.
  
• (18)FLUORODEOXYGLUCOSE PET IS PROGNOSTIC OF PROGRESSION-FREE AND OVERALL SURVIVAL IN LOCALLY ADVANCED PANCREAS CANCER TREATED WITH STEREOTACTIC RADIOTHERAPY Schellenberg, D., Quon, A., Minn, A. Y., Graves, E. E., Kunz, P., Ford, J. M., … Chang, D. T. (2010). (18)FLUORODEOXYGLUCOSE PET IS PROGNOSTIC OF PROGRESSION-FREE AND OVERALL SURVIVAL IN LOCALLY ADVANCED PANCREAS CANCER TREATED WITH STEREOTACTIC RADIOTHERAPY. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 77(5), 1420–25.
  
• Comparison of Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy as Adjuvant Therapy for Gastric Cancer Minn, A. Y., Hsu, A., La, T., Kunz, P., Fisher, G. A., Ford, J. M., … Chang, D. T. (2010). Comparison of Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy as Adjuvant Therapy for Gastric Cancer. CANCER, 116(16), 3943–52.
  
• Expression of p16(INK4A) But Not Hypoxia Markers or Poly Adenosine Diphosphate-Ribose Polymerase Is Associated With Improved Survival in Patients With Pancreatic Adenocarcinoma Chang, D. T., Chapman, C. H., Norton, J. A., Visser, B., Fisher, G. A., Kunz, P., … Pai, R. K. (2010). Expression of p16(INK4A) But Not Hypoxia Markers or Poly Adenosine Diphosphate-Ribose Polymerase Is Associated With Improved Survival in Patients With Pancreatic Adenocarcinoma. CANCER, 116(22), 5179–87.
  
• Intensity-Modulated Radiation Therapy Versus Conventional Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal Bazan, J. G., Hara, W., Hsu, A., Kunz, P. A., Ford, J., Fisher, G. A., … Chang, D. T. (2011). Intensity-Modulated Radiation Therapy Versus Conventional Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal. CANCER, 117(15), 3342–51.
  
• F-18-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases Zissen, M. H., Kunz, P., Subbarayan, M., Chin, F. T., Conti, P. S., Fisher, G. A., & Quon, A. (2011). F-18-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases. NUCLEAR MEDICINE COMMUNICATIONS, 32(5), 343–47.
  
• SINGLE-FRACTION STEREOTACTIC BODY RADIATION THERAPY AND SEQUENTIAL GEMCITABINE FOR THE TREATMENT OF LOCALLY ADVANCED PANCREATIC CANCER Schellenberg, D., Kim, J., Ciristman-Skieller, C., Chun, C. L., Columbo, L. A., Ford, J. M., … Koong, A. C. (2011). SINGLE-FRACTION STEREOTACTIC BODY RADIATION THERAPY AND SEQUENTIAL GEMCITABINE FOR THE TREATMENT OF LOCALLY ADVANCED PANCREATIC CANCER. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(1), 181–88.
  
• HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population: Clinicopathologic Analysis With Proposed Approach to HER2 Assessment Kunz, P. L., Mojtahed, A., Fisher, G. A., Ford, J. M., Chang, D. T., Balise, R. R., … Pai, R. K. (2012). HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population: Clinicopathologic Analysis With Proposed Approach to HER2 Assessment. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 20(1), 13–24.
  
• Pancreatic Endocrine Tumors With Major Vascular Abutment, Involvement, or Encasement and Indication for Resection Norton, J. A., Harris, E. J., Chen, Y., Visser, B. C., Poultsides, G. A., Kunz, P. C., … Jensen, R. T. (2011). Pancreatic Endocrine Tumors With Major Vascular Abutment, Involvement, or Encasement and Indication for Resection. ARCHIVES OF SURGERY, 146(6), 724–32.
  
• Advances in the treatment of gastroenteropancreatic neuroendocrine tumors. Kunz, P. L., & Fisher, G. A. (2010). Advances in the treatment of gastroenteropancreatic neuroendocrine tumors. Clinical and Experimental Gastroenterology, 3, 79–86.
  
• Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma Abelson, J. A., Murphy, J. D., Minn, A. Y., Chung, M., Fisher, G. A., Ford, J. M., … Chang, D. T. (2012). Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 82(4), E595–E601.
  
• Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors Kunz, P. L., He, A. R., Colevas, A. D., Pishvaian, M. J., Hwang, J. J., Clemens, P. L., … Marshall, J. L. (2012). Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors. INVESTIGATIONAL NEW DRUGS, 30(6), 2364–70.
  
• A rare case of an aldosterone secreting metastatic adrenocortical carcinoma and papillary thyroid carcinoma in a 31-year-old male. Wanta, S. M., Basina, M., Chang, S. D., Chang, D. T., Ford, J. M., Greco, R., … Kunz, P. L. (2011). A rare case of an aldosterone secreting metastatic adrenocortical carcinoma and papillary thyroid carcinoma in a 31-year-old male. Rare Tumors, 3(4).
  
• Pancreatic Neuroendocrine Tumors: Radiographic Calcifications Correlate with Grade and Metastasis Poultsides, G. A., Huang, L. C., Chen, Y., Visser, B. C., Pai, R. K., Jeffrey, R. B., … Norton, J. A. (2012). Pancreatic Neuroendocrine Tumors: Radiographic Calcifications Correlate with Grade and Metastasis. ANNALS OF SURGICAL ONCOLOGY, 19(7), 2295–2303.
  
• Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features Chang, D. T., Pai, R. K., Rybicki, L. A., DiMaio, M. A., Limaye, M., Jayachandran, P., … Pai, R. K. (2012). Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. MODERN PATHOLOGY, 25(8), 1128–39.
  
• Capecitabine-Induced Chest Pain Relieved by Diltiazem Ambrosy, A. P., Kunz, P. L., Fisher, G. A., & Witteles, R. M. (2012). Capecitabine-Induced Chest Pain Relieved by Diltiazem. AMERICAN JOURNAL OF CARDIOLOGY, 110(11), 1623–26.
  
• Long-Term Survivors of Gastric Cancer: A California Population-Based Study Kunz, P. L., Gubens, M., Fisher, G. A., Ford, J. M., Lichtensztajn, D. Y., & Clarke, C. A. (2012). Long-Term Survivors of Gastric Cancer: A California Population-Based Study. JOURNAL OF CLINICAL ONCOLOGY, 30(28), 3507–15.
  
• Seventh Edition (2010) of the AJCC/UICC Staging System for Gastric Adenocarcinoma: Is there Room for Improvement? Patel, M. I., Rhoads, K. F., Ma, Y., Ford, J. M., Visser, B. C., Kunz, P. L., … Poultsides, G. A. (2013). Seventh Edition (2010) of the AJCC/UICC Staging System for Gastric Adenocarcinoma: Is there Room for Improvement? ANNALS OF SURGICAL ONCOLOGY, 20(5), 1631–38.
  
• Neoadjuvant Imatinib for Borderline Resectable GIST Koontz, M. Z., Visser, B. M., & Kunz, P. L. (2012). Neoadjuvant Imatinib for Borderline Resectable GIST. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(12), 1477–82.
  
• Everolimus Causing Severe Hypertriglyceridemia and Acute Pancreatitis Subramaniam, S., Zell, J. A., & Kunz, P. L. (2013). Everolimus Causing Severe Hypertriglyceridemia and Acute Pancreatitis. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(1), 5–9.
  
• Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors Kunz, P. L., Reidy-Lagunes, D., Anthony, L. B., Bertino, E. M., Brendtro, K., Chan, J. A., … Yao, J. C. (2013). Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors. PANCREAS, 42(4), 557–77.
  
• Molecular analysis and prenatal diagnosis of human fumarase deficiency Coughlin, E. M., Christensen, E., Kunz, P. L., Krishnamoorthy, K. S., Walker, V., Dennis, N. R., … Shih, V. E. (1998). Molecular analysis and prenatal diagnosis of human fumarase deficiency. MOLECULAR GENETICS AND METABOLISM, 63(4), 254–262.
  
• Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer Shah, M. A., Wainberg, Z. A., Catenacci, D. V. T., Hochster, H. S., Ford, J., Kunz, P., … Bottaro, D. P. (2013). Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. PLOS ONE, 8(3).
  
• Penile metastases originating from a pancreatic primary tumor: a case report Tello, T. L., Zeidan, Y. H., Bush, K., Schwartz, E., Kunz, P., & Chang, D. T. (2012). Penile metastases originating from a pancreatic primary tumor: a case report. J Radiat Oncol, 2(1).
  
• Neuroendocrine Tumors Clinical Practice Guidelines in Oncology Kulke, M. H., Benson, A. B., Bergsland, E., Berlin, J. D., Blaszkowsky, L. S., Choti, M. A., … Dwyer, M. A. (2012). Neuroendocrine Tumors Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(6), 724–64.
  
• Reassessment of the Current American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Tumors Qadan, M., Ma, Y., Visser, B. C., Kunz, P. L., Fisher, G. A., Norton, J. A., & Poultsides, G. A. (2014). Reassessment of the Current American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Tumors. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 218(2), 188–95.
  
• Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness. Worhunsky, D. J., Krampitz, G. W., Poullos, P. D., Visser, B. C., Kunz, P. L., Fisher, G. A., … Poultsides, G. A. (2014). Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness. HPB , 16(4), 304–11.
  
• Postradiotherapy CA19-9 Kinetics Correlate With Outcomes in Patients With Pancreatic Adenocarcinoma Shultz, D. B., Chan, C., Shaffer, J. L., Kunz, P. L., Koong, A. C., & Chang, D. T. (2014). Postradiotherapy CA19-9 Kinetics Correlate With Outcomes in Patients With Pancreatic Adenocarcinoma. PANCREAS, 43(5), 777–83.
  
• A renaissance in therapeutic options for pancreatic neuroendocrine tumors. Kunz, P. L. (2012). A renaissance in therapeutic options for pancreatic neuroendocrine tumors. American Society of Clinical Oncology Educational Book / ASCO. American Society of Clinical Oncology. Meeting, 271–74.
  
• Single-versus Multifraction Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma: Outcomes and Toxicity Pollom, E. L., Alagappan, M., von Eyben, R., Kunz, P. L., Fisher, G. A., Ford, J. A., … Chang, D. T. (2014). Single-versus Multifraction Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma: Outcomes and Toxicity. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 90(4), 918–25.
  
• False positive 18F-fluorodeoxyglucose positron emission tomography/computed tomography liver lesion mimicking metastasis in 2 patients with gastroesophageal cancer. Paudel, N., Kunz, P. L., Poultsides, G. A., Koong, A. C., & Chang, D. T. (2014). False positive 18F-fluorodeoxyglucose positron emission tomography/computed tomography liver lesion mimicking metastasis in 2 patients with gastroesophageal cancer. Practical Radiation Oncology, 4(6), 368–71.
  
• Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Cives, M., Kunz, P. L., Morse, B., Coppola, D., Schell, M. J., Campos, T., … Strosberg, J. R. (2015). Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Endocrine-Related Cancer, 22(1), 1–9.
  
• Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors Narayanan, S., & Kunz, P. L. (2015). Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(1), 109–17.
  
• Neuroendocrine Tumors, Version 1.2015 Kulke, M. H., Shah, M. H., Benson, A. B., Bergsland, E., Berlin, J. D., Blaszkowsky, L. S., … Freedman-Cass, D. (2015). Neuroendocrine Tumors, Version 1.2015. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(1), 78–108.
  
• Beyond biologics: is there a role for systemic cytotoxic chemotherapy in neuroendocrine tumors? Narayanan, S., & Kunz, P. (2015). Beyond biologics: is there a role for systemic cytotoxic chemotherapy in neuroendocrine tumors? International Journal of Endocrine Oncology.
  
• Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma Nagpal, S., Recht, C. K., Bertrand, S., Thomas, R. P., Ajlan, A., Pena, J., … Recht, L. D. (2015). Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma. JOURNAL OF NEURO-ONCOLOGY, 123(2), 277–82.
  
• Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. Pollom, E. L., Alagappan, M., von Eyben, R., Kunz, P. L., Fisher, G. A., Ford, J. A., … Chang, D. T. (2014). Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. International Journal of Radiation Oncology, Biology, Physics, 90(4), 918–25.
  
• Carcinoid and neuroendocrine tumors: building on success. Kunz, P. L. (2015). Carcinoid and neuroendocrine tumors: building on success. Journal of Clinical Oncology , 33(16), 1855–1863.
  
• Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors. Narayanan, S., & Kunz, P. L. (2016). Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors. Hematology/Oncology Clinics of North America, 30(1), 163–77.
  
• DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications Liu, I. H., Ford, J. M., & Kunz, P. L. (2016). DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications. CANCER TREATMENT REVIEWS, 44, 1–9.
  
• DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications. Liu, I. H., Ford, J. M., & Kunz, P. L. (2016). DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications. Cancer Treatment Reviews, 44, 1–9.
  
• Neuroendocrine tumors of the pancreas: Degree of cystic component predicts prognosis. Cloyd, J. M., Kopecky, K. E., Norton, J. A., Kunz, P. L., Fisher, G. A., Visser, B. C., … Poultsides, G. A. (2016). Neuroendocrine tumors of the pancreas: Degree of cystic component predicts prognosis. Surgery, 160(3), 708–13.
  
• A Multi-institutional Analysis of Duodenal Neuroendocrine Tumors: Tumor Biology Rather than Extent of Resection Dictates Prognosis Margonis, G. A., Samaha, M., Kim, Y., Postlewait, L. M. L., Kunz, P., Maithel, S., … Pawlik, T. M. (2016). A Multi-institutional Analysis of Duodenal Neuroendocrine Tumors: Tumor Biology Rather than Extent of Resection Dictates Prognosis. JOURNAL OF GASTROINTESTINAL SURGERY, 20(6), 1098–1105.
  
• Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Kunz, P. L., Balise, R. R., Fehrenbacher, L., Pan, M., Venook, A. P., Fisher, G. A., … Bergsland, E. K. (2016). Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas, 45(10), 1394–1400.
  
• Phase 3 Trial of Lu-177-Dotatate for Midgut Neuroendocrine Tumors Strosberg, J., El-Haddad, G., Wolin, E., HENDIFAR, A., Yao, J., Chasen, B., … Krenning, E. (2017). Phase 3 Trial of Lu-177-Dotatate for Midgut Neuroendocrine Tumors. NEW ENGLAND JOURNAL OF MEDICINE, 376(2), 125–35.
  
• The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent. Scicinski, J., Fisher, G., Carter, C., Cho-Phan, C., Kunz, P., Ning, S., … Reid, T. (2015). The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent. Redox Biology, 5, 422-?
  
• Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. Kulke, M. H., Hörsch, D., Caplin, M. E., Anthony, L. B., Bergsland, E., Öberg, K., … Pavel, M. (2017). Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. Journal of Clinical Oncology , 35(1), 14–23.
  
• Lu-Dotatate for Midgut Neuroendocrine Tumors. Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., … Krenning, E. (2017). Lu-Dotatate for Midgut Neuroendocrine Tumors. New England Journal of Medicine, 376(2), 125–35.
  
• Understanding Neuroendocrine Tumors-A NET Gain. Kunz, P. L. (2017). Understanding Neuroendocrine Tumors-A NET Gain. JAMA Oncology.
  
• A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). Kunz, P. L., Catalano, P. J., Nimeiri, H. S., Fisher, G. A., Longacre, T. A., Schrijver, I., … Benson, A. B. (2015). A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). JOURNAL OF CLINICAL ONCOLOGY, 33(15).
  
• A novel biomarker panel examining response to adjuvant pancreatic cancer therapy in RTOG 9704 Heestand, G. M., Murphy, J. D., Moughan, J., Regine, W., Luo, J., Graber, M. S., … Koong, A. (2014). A novel biomarker panel examining response to adjuvant pancreatic cancer therapy in RTOG 9704. JOURNAL OF CLINICAL ONCOLOGY, 32(3).
  
• Outcomes and toxicity of SBRT for patients with unresectable pancreatic adenocarcinoma Pollom, E. L., Alagappan, M., Chan, C., Shultz, D., Kunz, P. L., Koong, A., & Chang, D. T. (2014). Outcomes and toxicity of SBRT for patients with unresectable pancreatic adenocarcinoma. JOURNAL OF CLINICAL ONCOLOGY, 32(3).
  
• Pretreatment lab values to predict overall survival in patients with primary unresectable pancreatic adenocarcinoma treated with SBRT Alagappan, M., Pollom, E. L., von Eyben, R., Kunz, P. L., Fisher, G. A., Ford, J. M., … Chang, D. T. (2015). Pretreatment lab values to predict overall survival in patients with primary unresectable pancreatic adenocarcinoma treated with SBRT. JOURNAL OF CLINICAL ONCOLOGY, 33(3).
  
• The Power of Trust. Mou, E., Schapira, L., & Kunz, P. (2018). The Power of Trust. JAMA Oncology.
  
• Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy Results of an Open-Label Extension of the TELECAST Phase 3 Clinical Trial Pavel, M., Benavent, M., Perros, P., Srirajaskanthan, R., Warner, R. R. P., Kulke, M. H., … Gross, D. J. (2018). Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy Results of an Open-Label Extension of the TELECAST Phase 3 Clinical Trial. PANCREAS, 47(3), 350.
  
• QOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors Strosberg, J., Wolin, E., Chasen, B., Kulke, M., Bushnell, D., Caplin, M., … Krenning, E. (2018). QOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors. PANCREAS, 47(3), 355.
  
• Weight Change Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome Weickert, M. O., Kaltsas, G., Hoersch, D., Lapuerta, P., Pavel, M., Valle, J. W., … Kulke, M. H. (2018). Weight Change Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome. PANCREAS, 47(3), 357–58.
  
• Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial Pavel, M., Gross, D. J., Benavent, M., Perros, P., Srirajaskanthan, R., Warner, R. R. P., … Garcia-Carbonero, R. (2018). Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. ENDOCRINE-RELATED CANCER, 25(3), 309–22.
  
• Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl Anthony, L., Ervin, C., Lapuerta, P., Kulke, M. H., Kunz, P., Bergsland, E., … DiBenedetti, D. B. (2017). Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl. CLINICAL THERAPEUTICS, 39(11), 2158–68.
  
• Carcinoid Syndrome Complicating a Pancreatic Neuroendocrine Tumor A Case Report Gerson, J. N., Witteles, R. M., Chang, D. T., Beygui, R. E., Iagaru, A. H., & Kunz, P. L. (2017). Carcinoid Syndrome Complicating a Pancreatic Neuroendocrine Tumor A Case Report. PANCREAS, 46(10), 1381–85.
  
• Phase I, Open-label, Dose-Escalation Study of SNX-5422 Plus Everolimus in Neuroendocrine Tumors (NETs) Gutierrez, M. E., Giaccone, G., Liu, S. V., Rajan, A., Guha, U., Halfdanarson, T., … Orlemans, E. O. (2018). Phase I, Open-label, Dose-Escalation Study of SNX-5422 Plus Everolimus in Neuroendocrine Tumors (NETs). PANCREAS, 47(3), 339.
  
• Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs: Analysis of the Completed TELESTAR Extension Period Hoersch, D., Kulke, M. H., Caplin, M. E., Anthony, L. B., Bergsland, E., Oberg, K., … Pavel, M. (2018). Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs: Analysis of the Completed TELESTAR Extension Period. PANCREAS, 47(3), 341–42.
  
• Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial. Strosberg, J., Wolin, E., Chasen, B., Kulke, M., Bushnell, D., Caplin, M., … Krenning, E. (2018). Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2018785865.
  
• NCCN Guidelines (R) Insights Neuroendocrine and Adrenal Tumors, Version 2.2018 Featured Updates to the NCCN Guidelines Shah, M. H., Goldner, W. S., Halfdanarson, T. R., Bergsland, E., Berlin, J. D., Halperin, D., … Zuccarino-Catania, G. (2018). NCCN Guidelines (R) Insights Neuroendocrine and Adrenal Tumors, Version 2.2018 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 16(6), 693–702.
  
• Loss of MGMT Protein Expression in Pancreatic Neuroendocrine Neoplasms Does Not Affect Overall Survival Zemek, A. J., Allen, J., Vairamuthu, H., Kunz, P. L., & Longacre, T. A. (2016). Loss of MGMT Protein Expression in Pancreatic Neuroendocrine Neoplasms Does Not Affect Overall Survival. MODERN PATHOLOGY, 29, 450A.
  
• Clinical and Immunohistochemical Features of Pancreatic Neuroendocrine Neoplasms DiMaio, M., Zemek, A., Allen, J., Vairamuthu, H., Balise, R., Kunz, P., & Longacre, T. (2015). Clinical and Immunohistochemical Features of Pancreatic Neuroendocrine Neoplasms. MODERN PATHOLOGY, 28, 133A.
  
• Loss of MGMT Protein Expression in Pancreatic Neuroendocrine Neoplasms Does Not Affect Overall Survival Zemek, A. J., Allen, J., Vairamuthu, H., Kunz, P. L., & Longacre, T. A. (2016). Loss of MGMT Protein Expression in Pancreatic Neuroendocrine Neoplasms Does Not Affect Overall Survival. LABORATORY INVESTIGATION, 96, 450A.
  
• Diagnostic discrepancies between second-opinion and referring pathology reports of neuroendocrine tumors Lin, H., Longacre, T. A., Khandelwal, V. H., Balise, R. R., & Kunz, P. L. (2013). Diagnostic discrepancies between second-opinion and referring pathology reports of neuroendocrine tumors. JOURNAL OF CLINICAL ONCOLOGY, 31(4).
  
• Clinical and Immunohistochemical Features of Pancreatic Neuroendocrine Neoplasms DiMaio, M., Zemek, A., Allen, J., Vairamuthu, H., Balise, R., Kunz, P., & Longacre, T. (2015). Clinical and Immunohistochemical Features of Pancreatic Neuroendocrine Neoplasms. LABORATORY INVESTIGATION, 95, 133A.
  
• Clinical and Immunohistochemical Features of Non-Pancreatic Gastrointestinal Neuroendocrine Neoplasms Zemek, A. J., DiMaio, M. A., Allen, J., Vairamuthu, H., Balise, R. R., Longacre, T. A., & Kunz, P. L. (2016). Clinical and Immunohistochemical Features of Non-Pancreatic Gastrointestinal Neuroendocrine Neoplasms. PANCREAS, 45(3), 487–88.
  
• Clinical and Immunohistochemical Features of Non-Pancreatic Gastrointestinal Neuroendocrine Neoplasms Zemek, A., DiMaio, M., Allen, J., Vairamuthu, H., Balise, R., Kunz, P., & Longacre, T. (2015). Clinical and Immunohistochemical Features of Non-Pancreatic Gastrointestinal Neuroendocrine Neoplasms. LABORATORY INVESTIGATION, 95, 201A.
  
• Diagnostic discrepancies between second-opinion and referring pathology reports of neuroendocrine tumors. Lin, H., Longacre, T. A., Khandelwal, V. H., Balise, R. R., & Kunz, P. L. (2013). Diagnostic discrepancies between second-opinion and referring pathology reports of neuroendocrine tumors. JOURNAL OF CLINICAL ONCOLOGY, 31(15).
  
• Clinical and Immunohistochemical Features of Non-Pancreatic Gastrointestinal Neuroendocrine Neoplasms Zemek, A., DiMaio, M., Allen, J., Vairamuthu, H., Balise, R., Kunz, P., & Longacre, T. (2015). Clinical and Immunohistochemical Features of Non-Pancreatic Gastrointestinal Neuroendocrine Neoplasms. MODERN PATHOLOGY, 28, 201A.
  
• Clinical and Immunohistochemical Features of High Grade Neuroendocrine Neoplasia of the Gastrointestinal Tract Zemek, A., DiMaio, M. A., Kwok, S. S., Kunz, P. L., & Longacre, T. A. (2015). Clinical and Immunohistochemical Features of High Grade Neuroendocrine Neoplasia of the Gastrointestinal Tract. PANCREAS, 44(2), 362.
  
• Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome Weickert, M. O., Kaltsas, G., Hoersch, D., Lapuerta, P., Pavel, M., Valle, J. W., … Kulke, M. H. (2018). Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome. CLINICAL THERAPEUTICS, 40(6), 952–62.
  
• Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst. Erdrich, J., Schaberg, K., Khodadoust, M. S., Zhou, L., Shelton, A. A., Visser, B. C., … Beausang, J. F. (2018). Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst. Cold Spring Harbor Molecular Case Studies.
  
• A phase II study of capecitabine, carboplatin, and bevacizumab for metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma. Kunz, P. L., Nandoskar, P., Koontz, M. Z., Ji, H., Ford, J. M., Balise, R. R., … Fisher, G. A. (2014). A phase II study of capecitabine, carboplatin, and bevacizumab for metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma. JOURNAL OF CLINICAL ONCOLOGY, 32(3).
  
• Long-Term Survivors of Pancreatic Cancer: A California Population-Based Study. Kardosh, A., Lichtensztajn, D. Y., Gubens, M. A., Kunz, P. L., Fisher, G. A., & Clarke, C. A. (2018). Long-Term Survivors of Pancreatic Cancer: A California Population-Based Study. Pancreas, 47(8), 958–66.
  
• Value of FDG PET/CT for the restaging of colorectal cancer after treatment with Erbitux. Mittra, E., Iagaru, A., Kunz, P., Quon, A., & Gambhir, S. (2009). Value of FDG PET/CT for the restaging of colorectal cancer after treatment with Erbitux. JOURNAL OF NUCLEAR MEDICINE, 50.
  
• Organoid Modeling of the Tumor Immune Microenvironment. Neal, J. T., Li, X., Zhu, J., Giangarra, V., Grzeskowiak, C. L., Ju, J., … Kuo, C. J. (2018). Organoid Modeling of the Tumor Immune Microenvironment. Cell, 175(7), 1972.
  
• Trust in neuroendocrine tumors: The importance of communication in rare and chronic malignancies Mou, E., Wittenberg, T. A., Kunz, P. L., & Schapira, L. (2018). Trust in neuroendocrine tumors: The importance of communication in rare and chronic malignancies. JOURNAL OF CLINICAL ONCOLOGY, 36(7).
  
• State of the Art: Evaluating the Role of Theranostics in G3 Neuroendocrine Neoplasms. Waseem, N. L., Aparici, C. M., & Kunz, P. L. (2019). State of the Art: Evaluating the Role of Theranostics in G3 Neuroendocrine Neoplasms. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine.
  
• DNA-Repair Defects in Pancreatic Neuroendocrine Tumors and Potential Clinical Applications Liu, I. H., Ford, J. M., & Kunz, P. L. (2015). DNA-Repair Defects in Pancreatic Neuroendocrine Tumors and Potential Clinical Applications. PANCREAS, 44(2), 355.
  
• Patient-Derived Organoids as an In Vitro Model of Neuroendocrine Tumors Liu, I. H., Neal, J. T., Zemek, A. J., Kunz, P. L., & Kuo, C. J. (2016). Patient-Derived Organoids as an In Vitro Model of Neuroendocrine Tumors. PANCREAS, 45(3), 467.
  
• Phase II study of epacadostat with pembrolizumab in metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma requiring paired biopsies. Kardosh, A., Tseng, D., Sahaf, B., Zomet, A., Krupa, J., Fisher, G. A., … Kunz, P. L. (2018). Phase II study of epacadostat with pembrolizumab in metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma requiring paired biopsies. JOURNAL OF CLINICAL ONCOLOGY, 36(4).
  
• A 20-year comparison of definitive chemoradiation with 5-FU versus capecitabine in anal cancer patients treated at Stanford. Pumpalova, Y. S., Kozak, M. M., von Eyben, R., Fisher, G. A., Kunz, P. L., Chang, D. T., & Haraldsdottir, S. (2018). A 20-year comparison of definitive chemoradiation with 5-FU versus capecitabine in anal cancer patients treated at Stanford. JOURNAL OF CLINICAL ONCOLOGY, 36(4).
  
• New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors: Q&A Discussion Phan, A. T., & Kunz, P. L. (2015). New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors: Q&A Discussion. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 13(5), 17.
  
• Biologics in gastrointestinal and pancreatic neuroendocrine tumors Liu, I. H., & Kunz, P. L. (2017). Biologics in gastrointestinal and pancreatic neuroendocrine tumors. JOURNAL OF GASTROINTESTINAL ONCOLOGY, 8(3), 457–65.
  
• The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors Strosberg, J. R., Halfdanarson, T. R., Bellizzi, A. M., Chan, J. A., Dillon, J. S., Heaney, A. P., … Bergsland, E. K. (2017). The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. PANCREAS, 46(6), 707–14.
  
• NETTER-1 Phase III in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate: Efficacy, Safety, QoL Results, and Subgroup Analysis Strosberg, J., Wolin, E., Chasen, B., Kulke, M., Bushnell, D., Caplin, M., … Krenning, E. (2017). NETTER-1 Phase III in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate: Efficacy, Safety, QoL Results, and Subgroup Analysis. PANCREAS, 46(3), 440.
  
• Long-Term Safety/Tolerability of Lanreotide Autogel/Depot (LAN) in Neuroendocrine Tumors (NETs) Patients With Carcinoid Syndrome (CS): The ELECT Long-Term Open-label Extension Vinik, A., Fisher, G., Kunz, P., Liyanage, N., Mirakhur, B., Lowenthal, S. P., … Wolin, E. (2017). Long-Term Safety/Tolerability of Lanreotide Autogel/Depot (LAN) in Neuroendocrine Tumors (NETs) Patients With Carcinoid Syndrome (CS): The ELECT Long-Term Open-label Extension. PANCREAS, 46(3), 437.
  
• Efficacy and Safety Results of Telotristat Ethyl in Patients With Carcinoid Syndrome During the Double-blind Treatment Period of the TELECAST Phase 3 Clinical Trial Pavel, M., Gross, D., Benavent, M., Caplin, M., Perros, P., Srirajaskanthan, R., … Garcia-Carbonero, R. (2017). Efficacy and Safety Results of Telotristat Ethyl in Patients With Carcinoid Syndrome During the Double-blind Treatment Period of the TELECAST Phase 3 Clinical Trial. PANCREAS, 46(3), 434–35.
  
• Efficacy of Lanreotide Depot/Autogel for Symptomatic Control of Carcinoid Syndrome (CS) in Neuroendocrine Tumor Patients: Follow-up Analysis of the ELECT Prospective, Randomized, Double-blind and Open-label Phases Fisher, G. A., Wolin, E. M., Kunz, P. L., Liyanage, N., Mirakhur, B., Lowenthal, S. P., … Vinik, A. (2017). Efficacy of Lanreotide Depot/Autogel for Symptomatic Control of Carcinoid Syndrome (CS) in Neuroendocrine Tumor Patients: Follow-up Analysis of the ELECT Prospective, Randomized, Double-blind and Open-label Phases. PANCREAS, 46(3), 433–34.
  
• Efficacy of Lanreotide Autogel/Depot (LAN) vs Placebo (PBO) for Symptomatic Control of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Study Wolin, E. M., Fisher, G. A., Kunz, P. L., Liyanage, N., Lowenthal, S. P., Mirakhur, B., … Vinik, A. (2016). Efficacy of Lanreotide Autogel/Depot (LAN) vs Placebo (PBO) for Symptomatic Control of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Study. AMERICAN JOURNAL OF GASTROENTEROLOGY, 111, S468.
  
• Longer Term Efficacy of Lanreotide Autogel/Depot (LAN) for Symptomatic Treatment of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Open Label Study Fisher, G. A., Wolin, E. M., Kunz, P. L., Liyanage, N., Mirakhur, B., Lowenthal, S. P., … Vinik, A. (2016). Longer Term Efficacy of Lanreotide Autogel/Depot (LAN) for Symptomatic Treatment of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Open Label Study. AMERICAN JOURNAL OF GASTROENTEROLOGY, 111, S457–S458.
  
• NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate. Strosberg, J. R., Wolin, E. M., Chasen, B., Kulke, M. H., Bushnell, D. L., Caplin, M. E., … Krenning, E. (2016). NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate. JOURNAL OF CLINICAL ONCOLOGY, 34(4).
  
• SAFETY AND EFFICACY OF LANREOTIDE DEPOT VS PLACEBO IN NEUROENDOCRINE TUMOR PATIENTS WITH A HISTORY OF CARCINOID SYNDROME AND PRIOR OCTREOTIDE THERAPY. Williams, D., Vinik, A., Wolin, E., Kunz, P., Lowenthal, S. P., & Fisher, G. (2016). SAFETY AND EFFICACY OF LANREOTIDE DEPOT VS PLACEBO IN NEUROENDOCRINE TUMOR PATIENTS WITH A HISTORY OF CARCINOID SYNDROME AND PRIOR OCTREOTIDE THERAPY. ONCOLOGY NURSING FORUM, 43(2), 133–34.
  
• Early results from a phase II study of RRx-001, a novel, triple epigenetic inhibitor, showing resensitization to irinotecan in colorectal cancer Reid, T., Fisher, G., Carter, C., Cho-Phan, C., Kunz, P., Oronsky, B., … Scicinski, J. (2015). Early results from a phase II study of RRx-001, a novel, triple epigenetic inhibitor, showing resensitization to irinotecan in colorectal cancer. CANCER RESEARCH, 75.
  
• Phase 2 Study of Fosbretabulin Tromethamine (CA4P) for the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic Pancreatic or Gastrointestinal Neuroendocrine Tumors/Carcinoid with Elevated Biomarkers Libutti, S. K., Anthony, L., Sosa, J. A., Kunz, P., Thomas, J., Cruikshank, S., … Wolin, E. M. (2016). Phase 2 Study of Fosbretabulin Tromethamine (CA4P) for the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic Pancreatic or Gastrointestinal Neuroendocrine Tumors/Carcinoid with Elevated Biomarkers. PANCREAS, 45(3), 478.
  
• Telotristat Etiprate Shows Benefit in Treating Patients With Carcinoid Syndrome That is Inadequately Controlled by Somatostatin Analog Therapy in the Phase 3 TELESTAR Clinical Trial Kulke, M. H., Hoersch, D., Caplin, M., Anthony, L., Bergsland, E., Oberg, K., … Pavel, M. (2016). Telotristat Etiprate Shows Benefit in Treating Patients With Carcinoid Syndrome That is Inadequately Controlled by Somatostatin Analog Therapy in the Phase 3 TELESTAR Clinical Trial. PANCREAS, 45(3), 478.
  
• Randomized Phase II Study of Everolimus (E) Versus Everolimus plus Bevacizumab (E plus B) in Patients (Pts) With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET), CALGB 80701 (Alliance) Kulke, M. H., Niedzwiecki, D., Foster, N. R., Fruth, B., Kunz, P. L., Kennecke, H., … Venook, A. P. (2016). Randomized Phase II Study of Everolimus (E) Versus Everolimus plus Bevacizumab (E plus B) in Patients (Pts) With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET), CALGB 80701 (Alliance). PANCREAS, 45(3), 477.
  
• Efficacy and Safety of Lanreotide Depot vs Placebo in Patients With Neuroendocrine Tumor and a History of Carcinoid Syndrome and Prior Octreotide Therapy Fisher, G. A., Wolin, E. M., Kunz, P., Liyanage, N., Gomez-Panzani, E., Lowenthal, S. P., … Vinik, A. (2016). Efficacy and Safety of Lanreotide Depot vs Placebo in Patients With Neuroendocrine Tumor and a History of Carcinoid Syndrome and Prior Octreotide Therapy. PANCREAS, 45(3), 475.
  
• Assessing Treatment Benefit of Telotristat Etiprate in Patients with Carcinoid Syndrome: Patient Exit Interviews Anthony, L., Hoersch, D., Ervin, C., Kulke, M. H., Pavel, M., Bergsland, E., … Lapuerta, P. (2016). Assessing Treatment Benefit of Telotristat Etiprate in Patients with Carcinoid Syndrome: Patient Exit Interviews. PANCREAS, 45(3), 470.
  
• RRx-001, a novel epigenetic modulator: Resensitization to previously failed therapy in the ongoing phase 2 colorectal cancer study, ROCKET Reid, T., Fisher, G., Carter, C., Cho-Phan, C., Kunz, P., Oronsky, B., … Scicinski, J. (2016). RRx-001, a novel epigenetic modulator: Resensitization to previously failed therapy in the ongoing phase 2 colorectal cancer study, ROCKET. CANCER RESEARCH, 76.
  
• Safety and Efficacy of Lanreotide Depot Versus Placebo in Neuroendocrine Tumor Patients With a History of Carcinoid Syndrome and Prior Octreotide Therapy Fisher, G. A., Wolin, E. M., Kunz, P., Liyanage, N., Gomez-Panzani, E., Lowenthal, S. P., … Vinik, A. (2015). Safety and Efficacy of Lanreotide Depot Versus Placebo in Neuroendocrine Tumor Patients With a History of Carcinoid Syndrome and Prior Octreotide Therapy. AMERICAN JOURNAL OF GASTROENTEROLOGY, 110, S1007.
  
• Gastroenteropancreatic Neuroendocrine Tumors: Diagnosis and Classification Kunz, P. L. (2015). Gastroenteropancreatic Neuroendocrine Tumors: Diagnosis and Classification. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 13(5), 4–6.
  
• Etirinotecan pegol (EP, NKTR-102) in the treatment of high-grade glioma (HGG): A phase 2 trial. Nagpal, S., Recht, C. K., Imtiaz, U., Bertrand, S., Thomas, B. P., Ajlan, A., … Recht, L. D. (2014). Etirinotecan pegol (EP, NKTR-102) in the treatment of high-grade glioma (HGG): A phase 2 trial. JOURNAL OF CLINICAL ONCOLOGY, 32(15).
  
• Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally advanced therapy. Denlinger, C. S., Sym, S. J., Bendell, J. C., Alsina, M., Watkins, D., Chao, Y., … Bang, Y.-J. (2014). Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally advanced therapy. JOURNAL OF CLINICAL ONCOLOGY, 32(15).
  
• Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E plus B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance) Kulke, M. H., Niedzwiecki, D., Foster, N. R., Fruth, B., Kunz, P. L., Kennecke, H. F., … Venook, A. P. (2015). Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E plus B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance). JOURNAL OF CLINICAL ONCOLOGY, 33(15).
  
• Phase II clinical trial of pasireotide LAR in patients with metastatic neuroendocrine tumors Strosberg, J. R., Jump, H., Valone, T., Weber, J., Khandelwal, V. H., & Kunz, P. L. (2014). Phase II clinical trial of pasireotide LAR in patients with metastatic neuroendocrine tumors. JOURNAL OF CLINICAL ONCOLOGY, 32(3).
  
• The Evolution of Modern Systemic Agents for Colorectal Cancer Heestand, G., Kunz, P., & Fisher, G. A. (2010). The Evolution of Modern Systemic Agents for Colorectal Cancer. LOWER GASTROINTESTINAL MALIGNANCIES, 1(2), 249–60.
  
• Examination of Factors Associated With Lymph Node Metastases in Lung Carcinoids Pathipati, M. P., Yohannan, T. K., Tian, L., Benson, J. A., Hornbacker, K., Berry, G. J., … Padda, S. K. (2019). Examination of Factors Associated With Lymph Node Metastases in Lung Carcinoids. PANCREAS, 48(3), 447.
  
• A Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors: ATrial of the ECOG-ACRIN Cancer Research Group (E2211) Kunz, P. L., Catalano, P., Nimeiri, H. S., Fisher, G. A., Longacre, T. A., Suarez, C. J., … Benson, A. B. (2019). A Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors: ATrial of the ECOG-ACRIN Cancer Research Group (E2211). PANCREAS, 48(3), 443.
  
• The Cost-Effectiveness of Initial vs Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors in the United States Barnes, J. I., Lin, J., Owens, D. K., Goldhaber-Fiebert, J. D., & Kunz, P. L. (2019). The Cost-Effectiveness of Initial vs Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors in the United States. PANCREAS, 48(3), 429.
  
• Lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III elect study. Fisher, G. A., Pommier, R. F., Wolin, E. M., Kunz, P. L., Liyanage, N., Lowenthal, S. W. P., … Vinik, A. (2017). Lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III elect study. JOURNAL OF CLINICAL ONCOLOGY, 35.
  
• Postradiotherapy CA19-9 Kinetics Correlate With Outcomes in Patients With Pancreatic Adenocarcinoma. Shultz, D. B., Chan, C., Shaffer, J. L., Kunz, P. L., Koong, A. C., & Chang, D. T. (2014). Postradiotherapy CA19-9 Kinetics Correlate With Outcomes in Patients With Pancreatic Adenocarcinoma. Pancreas, 43(5), 777–83.
  
• Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst Erdrich, J., Schaberg, K. B., Khodadoust, M. S., Zhou, L., Shelton, A. A., Visser, B. C., … Beausang, J. F. (2018). Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst. COLD SPRING HARBOR MOLECULAR CASE STUDIES, 4(5).
  
• Organoid Modeling of the Tumor Immune Microenvironment Neal, J. T., Li, X., Zhu, J., Giangarra, V., Grzeskowiak, C. L., Ju, J., … Kuo, C. J. (2018). Organoid Modeling of the Tumor Immune Microenvironment. CELL, 175(7), 1972-+.
  
• Efficacy of lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in patients with neuroendocrine tumor (NET) previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III ELECT study. Pommier, R. F., Fisher, G. A., Wolin, E. M., Kunz, P. L., Liyanage, N., Lowenthal, S. W. P., … Vinik, A. (2017). Efficacy of lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in patients with neuroendocrine tumor (NET) previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III ELECT study. JOURNAL OF CLINICAL ONCOLOGY, 35(4).
  
• Long-Term Survivors of Pancreatic Cancer: A California Population-Based Study Kardosh, A., Lichtensztajn, D. Y., Gubens, M. A., Kunz, P. L., Fisher, G. A., & Clarke, C. A. (2018). Long-Term Survivors of Pancreatic Cancer: A California Population-Based Study. PANCREAS, 47(8), 958–66.
  
• Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With Lu-177-Dotatate in the Phase III NETTER-1 Trial Strosberg, J., Wolin, E., Chasen, B., Kulke, M., Bushnell, D., Caplin, M., … Krenning, E. (2018). Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With Lu-177-Dotatate in the Phase III NETTER-1 Trial. JOURNAL OF CLINICAL ONCOLOGY, 36(25), 2578-+.
  
• Prognostic value of volumetric parameters calculated from Ga-68-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors Toriihara, A., Baratto, L., Nobashi, T., Park, S., Hatami, N., Davidzon, G., … Iagaru, A. (2018). Prognostic value of volumetric parameters calculated from Ga-68-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors. JOURNAL OF NUCLEAR MEDICINE, 59.
  
• Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial. Strosberg, J. R., Wolin, E. M., Chasen, B., Kulke, M. H., Bushnell, D. L., Caplin, M. E., … Krenning, E. (2017). Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial. JOURNAL OF CLINICAL ONCOLOGY, 35(4).
  
• The Power of Trust Mou, E., Schapira, L., & Kunz, P. (2018). The Power of Trust. JAMA ONCOLOGY, 4(9), 1173–74.
  
• Association of weight change with telotristat ethyl in the treatment of carcinoid syndrome. Weickert, M., Kaltsas, G., Horsch, D., Lapuerta, P., Pavel, M., Valle, J. W., … Kulke, M. H. (2017). Association of weight change with telotristat ethyl in the treatment of carcinoid syndrome. JOURNAL OF CLINICAL ONCOLOGY, 35.